A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment-Reference-Cited by-同舟云学术

A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment

Published:2019-12 Issue:12 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kempker Russell R.¹^ORCID,Alghamdi Wael A.²^ORCID,Al-Shaer Mohammad H.³^ORCID,Burch Gena³^ORCID,Peloquin Charles A.³^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

2. Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia

3. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA

Abstract

Tuberculosis (TB) and hepatitis C virus (HCV) infections are both major public health problems. Despite high rates of coinfection, there is scarce literature addressing the convergence of the two diseases. One particularly unexplored area is the potential for simultaneous treatment of TB and HCV which would allow for leveraging an extensive global TB treatment infrastructure to help scale up HCV treatment.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01215-19

Reference111 articles.

1. WHO. 2018. Global tuberculosis report 2018. World Health Organization, Geneva, Switzerland.

2. WHO. 2017. Global hepatitis report 2017. World Health Organization, Geneva, Switzerland.

3. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia